NINGBO INNO PHARMCHEM CO.,LTD. is proud to supply Doxofylline, a pharmaceutical intermediate that embodies scientific advancement in respiratory care. Understanding the science behind this compound reveals its profound therapeutic potential.

Doxofylline, chemically known as 7-(1,3-dioxolan-2-ylmethyl)-theophylline, is a derivative of the well-known methylxanthine, theophylline. While it shares the fundamental pharmacological class with theophylline, its structural modification at the N7 position of the purine ring imbues it with distinct properties. This modification is key to its improved clinical profile.

The primary mechanism of action for Doxofylline, much like theophylline, involves the inhibition of phosphodiesterase (PDE) enzymes. Specifically, it targets PDE3 and PDE4. By inhibiting these enzymes, Doxofylline increases intracellular levels of cyclic adenosine monophosphate (cAMP). Elevated cAMP in airway smooth muscle cells leads to smooth muscle relaxation, resulting in bronchodilation. This process is critical for alleviating the bronchoconstriction experienced by individuals with asthma and COPD.

Furthermore, Doxofylline is recognized for its anti-inflammatory effects. It is thought to exert these effects, in part, through the activation of histone deacetylase 2 (HDAC2). Reduced HDAC2 activity is associated with the inflammatory processes in asthma. By enhancing HDAC2 activity, Doxofylline can help to downregulate the expression of pro-inflammatory genes, thereby reducing airway inflammation. This is a significant advantage, as chronic inflammation is a hallmark of severe respiratory diseases.

One of the most compelling aspects of Doxofylline is its reduced affinity for adenosine receptors compared to theophylline. Adenosine receptor antagonism is linked to several of theophylline's undesirable side effects, including CNS stimulation, cardiac arrhythmias, and gastrointestinal upset. Doxofylline's weaker interaction with these receptors translates to a better safety profile and enhanced tolerability. This makes it a more suitable option for long-term use, especially in patient populations where theophylline's side effects are a concern, such as in pediatric asthma management.

The therapeutic applications of Doxofylline extend to both asthma and COPD. Its bronchodilatory and anti-inflammatory actions make it an effective agent for symptom relief and disease control. The lack of a requirement for routine blood monitoring further simplifies its use, allowing for consistent therapeutic levels without the need for frequent clinical intervention.

NINGBO INNO PHARMCHEM CO.,LTD. is committed to providing high-quality Doxofylline that meets the rigorous demands of the pharmaceutical industry. By sourcing our Doxofylline, you are partnering with a supplier dedicated to advancing respiratory medicine through science-backed intermediates. Explore how Doxofylline can empower your next therapeutic development.